Welsh AMs call for greater awareness of GP Palliative Care Registers

Welsh AMs call for greater awareness of GP Palliative Care Registers

July 18 2018 Targets should be set to increase the number of people requiring palliative care to...

BLF highlights decline in stop smoking prescriptions

BLF highlights decline in stop smoking prescriptions

July 18 2018 There has been a 75% decline in stop smoking treatments being prescribed by GPs and...

NICE says to restrict antibiotics in COPD

NICE says to restrict antibiotics in COPD

July 13 2018 Draft guidance is calling for health professionals to consider the risk of...

NICE updates guideline on rheumatoid arthritis

NICE updates guideline on rheumatoid arthritis

July 13 2018 NICE has issued a new version of its guideline on the management of rheumatoid...

Community pharmacy option for antihypertensives referral sees little increase in GP workload

Community pharmacy option for antihypertensives referral sees little increase in GP workload

July 11 2018 Community pharmacy referrals for hypertensive patients under the New Medicines...

  • Welsh AMs call for greater awareness of GP Palliative Care Registers

    Welsh AMs call for greater awareness of GP Palliative Care Registers

    Wednesday, 18 July 2018 17:52
  • BLF highlights decline in stop smoking prescriptions

    BLF highlights decline in stop smoking prescriptions

    Wednesday, 18 July 2018 17:48
  • NICE says to restrict antibiotics in COPD

    NICE says to restrict antibiotics in COPD

    Friday, 13 July 2018 13:05
  • NICE updates guideline on rheumatoid arthritis

    NICE updates guideline on rheumatoid arthritis

    Friday, 13 July 2018 12:58
  • Community pharmacy option for antihypertensives referral sees little increase in GP workload

    Community pharmacy option for antihypertensives referral sees little increase in GP workload

    Wednesday, 11 July 2018 13:17

a alert imageJanuary 10 2018

The medicines regulator has highlighted the different strengths of co-dydramol in its latest Drug Safety Update. 

For many years co-dydramol has been available at a fixed ratio of 1:50, combining dihydrocodeine 10mg and paracetamol 500mg. However, the MHRA’s latest DSU is advising that new strengths containing proportionately greater amounts of dihydrocodeine – co-dydramol 20/500 mg and co-dydramol 30/500 mg tablets – are becoming available.

Health professionals should take care to ensure the intended strength is clearly prescribed and the correct strength is dispensed. If the prescribed strength is unclear, the person dispensing should contact the prescriber for clarification, says the MHRA. It is also asking that health professionals “report suspected adverse drug reactions with opioids, including any harm from medication error, via the Yellow Card Scheme.”

The DSU newsletter of January 6 also asks health professionals to ask if a patient has been using herbal medicines when reporting any suspected adverse drug reaction. If herbal medicines or traditional Chinese medicines have been used, this information should be included on the Yellow Card scheme report.

Ideally, information about a herbal product should include the brand name, the list of ingredients, a copy of the package labelling if available, and any manufacturer details. Patients should also be advised to check for the Traditional Herbal Registration Certification Mark.

Another medicine included in the DSU newsletter is daclizumab (daclizumab beta), which is “now restricted to adults with relapsing multiple sclerosis who have had an inadequate response to at least two other disease-modifying therapies (DMTs) and for whom other DMTs are contraindicated or unsuitable.”

The MHRA is advising that patients with pre-existing hepatic disease or hepatic impairment should not use daclizumab. Before initiating treatment, patients should also be screened for hepatitis B and C viral infections. Treatment should also be closely monitored to check for any developing liver problems.

Initiation is not recommended in certain other circumstances: with raised aminotransferase (ALT) or aspartate aminotransferase (AST) levels or in those with autoimmune conditions other than multiple sclerosis. Caution should also be taken in prescribing daclizumab “in patients receiving other medication that may be hepatotoxic, including over-the-counter products and herbal medicines.”

Links:
MHRA Drug Safety Update: monthly PDF newsletters        
MHRA Drug Safety Update: monthly PDF newsletter. January 6 2018. 11;6.                 
Co-dydramol DSU             
Herbal medicines DSU    
Daclizumab DSU                

Professional News

July 18 2018 Targets should be set to increase the number of people requiring palliative care to be included on General Practice Palliative Care Registers in Wales. There should also be measures to...
July 11 2018 Community pharmacy referrals for hypertensive patients under the New Medicines Service has not increased GP workload appreciably. Analysis of 131,419 patient records in England has...